Impact of Mepolizumab on Exacerbations in the US Medicare Population
Impact of Mepolizumab on Exacerbations in the US Medicare Population is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Impact of Mepolizumab on Exacerbations in the US Medicare Population have?
Impact of Mepolizumab on Exacerbations in the US Medicare Population has 3 citations in the OpenAlex counts ScholarIQ stores.
When was Impact of Mepolizumab on Exacerbations in the US Medicare Population published?
Impact of Mepolizumab on Exacerbations in the US Medicare Population has 2022 year in the ScholarIQ index.
What is the open-access status of Impact of Mepolizumab on Exacerbations in the US Medicare Population?
Impact of Mepolizumab on Exacerbations in the US Medicare Population has hybrid oa status in the ScholarIQ index.
What is the DOI of Impact of Mepolizumab on Exacerbations in the US Medicare Population?
The DOI for Impact of Mepolizumab on Exacerbations in the US Medicare Population is on the source record.
What is the PMID of Impact of Mepolizumab on Exacerbations in the US Medicare Population?
The PMID for Impact of Mepolizumab on Exacerbations in the US Medicare Population is on the source record.
What is the OpenAlex record for Impact of Mepolizumab on Exacerbations in the US Medicare Population?
The OpenAlex for Impact of Mepolizumab on Exacerbations in the US Medicare Population is on the source record.